Syrian Arab RepublicTuberculosis profile
Population  2015 19 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.021 (0.019–0.022) 0.11 (0.1–0.12)
Mortality (HIV+TB only) 0 (–) 0 (–)
Incidence  (includes HIV+TB) 3.6 (2.8–4.6) 20 (15–25)
Incidence (HIV+TB only)        
Incidence (MDR/RR-TB)** 0.34 (0.21–0.47) 1.8 (1.1–2.5)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 0.2 (0.091–0.3) 1.1 (0.63–1.7) 1.3 (0.72–2)
Males 0.22 (0.14–0.3) 2.1 (1.5–2.6) 2.3 (1.7–2.9)
Total 0.42 (0.29–0.55) 3.2 (2.7–3.7) 3.6 (2.8–4.6)
TB case notifications, 2015  
Total cases notified 2 992
Total new and relapse 2 908
          - % tested with rapid diagnostics at time of diagnosis 3%
          - % with known HIV status <1%
          - % pulmonary 58%
          - % bacteriologically confirmed among pulmonary 79%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 80% (64–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.01 (0–0.01)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 3 20%
          - on antiretroviral therapy 3 100%
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  150
(100–200)
Estimated % of TB cases with MDR/RR-TB 8% (4.9–11) 18% (11–27)  
% notified tested for rifampicin resistance 9% 56% 339
MDR/RR-TB cases tested for resistance to second-line drugs   0
Laboratory-confirmed cases MDR/RR-TB: 4, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 9, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 70% 3 390
Previously treated cases, excluding relapse, registered in 2014 69% 95
HIV-positive TB cases, all types, registered in 2014    
MDR/RR-TB cases started on second-line treatment in 2013 100% 2
XDR-TB cases started on second-line treatment in 2013   0
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2016  
National TB budget (US$ millions)  
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-08 Data: www.who.int/tb/data